US BANCORP \DE\ - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 115 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q2 2021$09
-79.5%
0.00%
Q1 2020$0440.0%0.00%
Q4 2019$0440.0%0.00%
Q3 2019$0440.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2021
NameSharesValueWeighting ↓
Defender Capital, LLC. 5,036,720$14,354,0004.77%
BROADWOOD CAPITAL INC 34,005,379$96,915,0004.33%
Prescott General Partners LLC 1,851,851$5,278,0000.17%
Raffles Associates 43,590$124,0000.10%
Laidlaw Wealth Management LLC 123,730$353,0000.09%
DCF Advisers, LLC 74,500$212,0000.08%
Beirne Wealth Consulting Services, LLC 45,000$128,0000.07%
Strategic Wealth Investment Group, LLC 64,232$183,0000.06%
Paradigm, Strategies in Wealth Management, LLC 19,775$56,0000.05%
Fort Sheridan Advisors LLC 47,931$137,0000.05%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders